

Collaboration Opportunity: Unravelling barriers in current day PD-L1 testing to optimise future testing


The rapid expansion observed in PD-L1/PD-1 precision medicine in the last few years has resulted in confusion regarding how optimal PD-L1 testing should be performed, with:

1. Commercially available assays existing in the market alongside numerous standalone antibodies
2. Recommendations regarding scoring algorithms and clinical cut-offs varying depending on the assay-indication combination

Why join the collaboration:

- ✓ Receive one free of charge PD-L1 cell microarray block covering a dynamic range of PD-L1. The block will yield 300 – 350 cut slides for you to use as required. Sample types include: Breast ductal carcinoma, Osteosarcoma, Fibrosarcoma and T-cell non-Hodgkin lymphoma.
- ✓ Benchmark yourself and participate in a Peer review article with other PD-L1 users who have chosen to participate in this collaboration to understand how you compare to your peers and what you could do to optimise testing

Next steps to joining the collaboration:



Discover DXRX Collaborations